Full Text View
Tabular View
No Study Results Posted
Related Studies
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
This study has been terminated.
Study NCT00228592   Information provided by Cubist Pharmaceuticals
First Received: September 27, 2005   Last Updated: February 12, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B
Liver Transplantation
Additional conditions recognized in this trial
Hepatitis
Liver Diseases
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Virus Diseases
Interventions listed in this trial
HepeX-B
Hepatitis B Immune Globulin (HBIg)
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Cubist Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services